Subcutaneous apomorphine and the nonmotor features of Parkinson's disease

Parkinson's disease (PD) is a heterogeneous, progressive neurodegenerative disorder in which nonmotor manifestations (autonomic, sleep-related, neuropsychiatric, and sensory) constitute integral components of the disease continuum, exerting a disproportionate influence on quality of life, long-term disability, and caregiver burden. These features comprise both persistent components intrinsic to neurodegeneration and state-dependent fluctuations mechanistically linked to the oscillating dopaminergic tone imposed by pulsatile oral therapy. Apomorphine occupies a singular pharmacological position among the PD armamentarium, distinguished by a receptor binding profile, physicochemical properties, and pharmacokinetics that set it apart from other dopamine agonists and from levodopa-based therapies. Nearly four decades of clinical experience have established its efficacy in attenuating motor fluctuations and dyskinesias via continuous subcutaneous infusion (CSAI). Its effects on the nonmotor dimension of PD remain however incompletely characterized, reflecting both limited research investment and methodological constraints inherent to nonmotor outcome assessment and to apomorphine therapy itself. This narrative review and expert opinion examines the pharmacological basis for apomorphine's putative nonmotor efficacy, clinical evidence across individual nonmotor domains and iatrogenic considerations before reassessing apomorphine's therapeutic positioning within the device-aided therapy landscape. Nonmotor features should be regarded as primary determinants of treatment decision-making rather than secondary endpoints. The emerging concept of "fluctuation-dominant" PD provides a framework in which nonmotor fluctuation burden alone may constitute sufficient indication for CSAI, with direct implications for patient selection, timing of initiation, and redefinition of therapeutic goals beyond motor control.